Karyopharm Therapeutics Inc 2026年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 For the transition period fromtoCommission file number: 001-36167 Karyopharm Therapeutics Inc.(Exact name of registrant as specified in its charter) 26-3931704(I.R.S. EmployerIdentification Number) (617) 658-0600(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has beensubject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was requiredto submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐ Smaller reporting company☒ Non-accelerated filer☒ Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of May 7, 2026, there were 22,662,943 shares of Common Stock, $0.0001 par value per share, outstanding. TABLE OF CONTENTS PART I-FINANCIAL INFORMATION2 Item 1.Condensed Consolidated Financial Statements (Unaudited)2Condensed Consolidated Balance Sheets2Condensed Consolidated Statements of Operations3Condensed Consolidated Statements of Comprehensive Income (Loss)4Condensed Consolidated Statements of Cash Flows5Condensed Consolidated Statements of Stockholders’ Deficit6Notes to Condensed Consolidated Financial Statements7Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations20Item 3.Quantitative and Qualitative Disclosures About Market Risk29Item 4.Controls and Procedures29 PART II-OTHER INFORMATION Item 1A.Risk FactorsItem 5.Other InformationItem 6.ExhibitsSignatures KARYOPHARM THERAPEUTICS INC.CONDENSED CONSOLIDATED BALANCE SHEETS(unaudited)(in thousands, except per share amounts) KARYOPHARM THERAPEUTICS INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(unaudited)(in thousands, except per share amounts) Table of Contents KARYOPHARM THERAPEUTICS INC.CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)(unaudited)(in thousands) See accompanying notes to condensed consolidated financial statements. KARYOPHARM THERAPEUTICS INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(unaudited)(in thousands) KARYOPHARM THERAPEUTICS INC.CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT(unaudited)(in thousands) KARYOPHARM THERAPEUTICS INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 1. Nature of Business, Basis of Presentation and Segment Information Nature of Business Karyopharm Therapeutics Inc., a Delaware corporation (collectively with its subsidiaries, the “Company,” “we,” “us,” or“our”), is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery,development and commercialization of first-in-class drugs directed against nuclear export for the treatment of cancer. Our scientificexpertise is based upon an understanding of the regulation of intracellular communication between the nucleus and the cytoplasm.We have discovered and are developing and commercializing novel, small molecule XPO1 inhibitor compounds that inhibit thenuclear export protein exportin 1. Our primary focus is on marketing XPOVIO®(selinexor) in its currently approved indications, aswell as developing and seeking regulatory approval of selinexor as an oral agent targeting multiple high unmet need cancerindications, including our lead clinical programs in myelofibrosis and endometrial cancer and our other late-stage clinical programin multiple myeloma. We were incorporated in Delaware on December 22, 2008 and have a principal place of business in Newton,Massachusetts. Our lead asset, XPOVIO, received its initial U.S. approval from the U.S. Food and Drug Administration in July 2019 and iscurrentl